Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Myeloid cells comprise a major component of the tumor microenvironment (TME) that promotes tumor growth and immune evasion. By employing a small-molecule inhibitor of glutamine metabolism, not only were we able to inhibit tumor growth, but we markedly inhibited the generation and recruitment of myeloid-derived suppressor cells (MDSCs). Targeting tumor glutamine metabolism led to a decrease in CSF3 and hence recruitment of MDSCs as well as immunogenic cell death, leading to an increase in inflammatory tumor-associated macrophages (TAMs). Alternatively, inhibiting glutamine metabolism of the MDSCs themselves led to activation-induced cell death and conversion of MDSCs to inflammatory macrophages. Surprisingly, blocking glutamine metabolism also inhibited IDO expression of both the tumor and myeloid-derived cells, leading to a marked decrease in kynurenine levels. This in turn inhibited the development of metastasis and further enhanced antitumor immunity. Indeed, targeting glutamine metabolism rendered checkpoint blockade-resistant tumors susceptible to immunotherapy. Overall, our studies define an intimate interplay between the unique metabolism of tumors and the metabolism of suppressive immune cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, a prodrug of 6‐diazo‐5‐oxo‐l‐norleucine (DON) that blocks glutamine metabolism in myeloid precursor cells can differentiate monocytes into anti‐tumor TAMs, leading to tumor regression in mouse models [56].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Tang, Z., Li, C., Kang, B., Gao, G., Li, C., & Zhang, Z. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx247 · Cited by 9,849
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · cited 1×
“Yet, in spite of these successes it is clear that not all cancers respond to checkpoint blockade alone and even amongst responsive cancers, not all patients respond (52, 60-62).”
BackgroundPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Yet, in spite of these successes it is clear that not all cancers respond to checkpoint blockade alone and even amongst responsive cancers, not all patients respond (52, 60-62).”
BackgroundMacrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 1×
“Macrophages, which constitute a major component of tumors, are involved in cancer initiation, progression, angiogenesis, metastasis, and creating an immune suppressive environment (4-7).”
BackgroundUnderstanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · cited 1×
“Such an environment favors the residency of suppressive myeloid cells such as MDSCs, TANs, and TAMs, all of which contribute to promoting tumor growth, angiogenesis, metastasis, and immune escape (51).”
BackgroundThe emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 1×
“Alternatively, suppressive immune cells, that are metabolically distinct from effector cells, thrive in the TME (1-3).”
BackgroundPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089 · cited 1×
“Macrophages, which constitute a major component of tumors, are involved in cancer initiation, progression, angiogenesis, metastasis, and creating an immune suppressive environment (4-7).”
Background
Cited by
Items 301–400 of 471
Immune Cell Metabolism and Immuno-Oncology
Patel, C. H., & Powell, J. D. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-042605 · Cited by 11
Self-citationJi, H., Yuan, L., Jiang, W., Jiang, Y., Jiang, M., Sun, X., & Chen, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-47257-8 · Cited by 10
Role of Nutrients Regulating Myeloid Derived Suppressor Cells in Cancer: A Scoping Review
Pérez-Peláez, B., Jiménez‐Cortegana, C., de la Cruz‐Merino, L., & Sánchez‐Margalet, V. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46090549 · Cited by 8
“The targeting of glutamine promotes MDSC apoptosis and the downregulation of MDSC-related molecules, such as indoleamine 2,3-dioxygenase, which produces a deficiency of L-tryptophan and, consequently, T-cell anergy [27,44].”
BackgroundMa, G., Jia, H., Li, Z., Zhang, X., Wang, L., Zhang, Z., Xiao, Y., Liang, Z., Li, D., Chen, Y., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0039 · Cited by 11
Influence of the Metabolism on Myeloid Cell Functions in Cancers: Clinical Perspectives
Boyer, T., Blaye, C., Larmonier, N., & Domblides, C. (2022) · Cells · doi:10.3390/cells11030554 · Cited by 8
“In MDSCs, glutamine consumption favors the expansion of MDSC pools within tumors [33].”
BackgroundSong, L., Wei, X., Zhang, X., & Lu, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1241454 · Cited by 8
“There is a strong correlation between immune cell infiltration in the TME and glutamine metabolism, according to several recent studies (Oh et al., 2020; Yang et al., 2021).”
ResultCOVID‐19 Metabolomic‐Guided Amino Acid Therapy Protects from Inflammation and Disease Sequelae
Ming, S., Qu, S., Wu, Y., Wei, J., Zhang, G., Jiang, G., & Huang, X. (2023) · Advanced Biology · doi:10.1002/adbi.202200265 · Cited by 9
Extrinsic and Cell-Intrinsic Stress in the Immune Tumor Micro-Environment
Ummarino, A., Calà, N., & Allavena, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212403 · Cited by 9
Yin, Y., Yan, C., Pei, X., Rao, J., Wu, L., Xue, Y., Sun, H., & Sheng, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1736082 · Cited by 11
Mbah, N. E., Sutton, D., Hong, H. S., Singhal, R., Menjivar, R. E., Perricone, M. D., Giza, H., Sajjakulnukit, P., Myers, A. L., Nwosu, Z. C., et al. (2026) · Cancer & Metabolism · doi:10.1186/s40170-026-00428-3 · Cited by 9
Benito-Lopez, J. J., Marroquin-Muciño, M., Perez-Medina, M., Chavez-Dominguez, R., Aguilar‐Cázares, D., Galicia-Velasco, M., & López-González, J. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1101503 · Cited by 7
Ko, J. M. Y., Guo, C., Leung, A. K.-K., Chan, S. C.-Y., Lo, A. W. I., Tao, L., Ng, H. Y., Wong, C. W.-Y., Law, S. Y.-K., Wong, Y., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03113-2 · Cited by 7
Xing, N., Yan, J., Gao, R., Zhang, A., He, H., Zheng, M., & Li, G. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00852-z · Cited by 6
“This transformation highlights the potential of Gln metabolism modulation as a means to reprogram tumor-associated macrophages from an M2 to an M1 state, thereby potentiating anti-tumor immunity [9].”
Chen, C., Guo, W., Wang, H., Cao, L., & Bai, O. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1659011 · Cited by 8
The essential link: How STAT3 connects tumor metabolism to immunity
Shu, Z., & Tong, J. (2024) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2024.195028 · Cited by 6
Xie, L., Zhang, Y., Niu, X., Jiang, X., Kang, Y., Diao, X., Fang, J., Yu, Y., & Yao, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1524439 · Cited by 12
“Additionally, larger tumors recruit more TAMs and myeloid-derived suppressor cells (MDSCs), which suppress effector T cell function and promote tumor invasion and metastasis (63, 64).”
Voor, S. F., Cooper, A. J. L., & Pinto, J. T. (2025) · Analytical Biochemistry · doi:10.1016/j.ab.2025.115989 · Cited by 6
Myeloid metabolism and its role in immunotherapy of cancer
Garlatti, V., Consonni, F. M., Ballerini, G., Incerti, M., Balboni, A., Cassatella, M. A., & Sica, A. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012127 · Cited by 6
“90 Accordingly, hampering glutaminase 1 activity, which promotes the production of α -ketoglutarate ( α -KG) from Gln, can profoundly affect MDSCs expansion and formation.”
Airway immunometabolic responses during pulmonary bacterial and viral infections
Wadhwa, R., Tang, E. W., Wong, L. Y. R., & Lung, T. W. F. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116614 · Cited by 5
Amino acid metabolic reprogramming drives pathogenesis and therapy in hematologic malignancies
Ren, D., Liu, R., Wei, L., Li, L., Lv, X., Xia, X., & Lei, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-04093-8 · Cited by 5
“The activation of c-Myc is thus closely associated with tumor initiation, progression, and clinical outcome [61].”
Cui, J., Xia, Y., & Song, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1715170 · Cited by 7
“Moreover, blocking glutamine metabolism also inhibits the expression of indoleamine 2,3-dioxygenase (IDO) in tumors and myeloid - derived cells, leading to a substantial decline in kynurenine levels, thus further intensifying the anti-tumor immune response (41).”
Wang, Y., Dong, Q., Yuan, M., Hu, J., Lin, P., Yan, Y., Yan, Y., & Wang, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113892 · Cited by 5
Alt, J., Gori, S. S., Lemberg, K. M., Pal, A., Veeravalli, V., Wu, Y., Aguilar, J. M. H., Dash, R. P., Tenora, L., Majer, P., et al. (2021) · Current Drug Metabolism · doi:10.2174/1389200222666210831125041 · Cited by 5
Self-citationFan, H., Zhang, S., Yuan, Y., Chen, S., Li, W., Wang, Z., Xiang, Y., Li, J., Ma, X., & Liu, Y. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1104738 · Cited by 6
“A previous study discovered that targeting glutamine metabolism inhibited the generation and recruitment of myeloid-derived suppressor cells (MDSCs) and promotes the generation of antitumor inflammatory tumorassociated macrophages (TAMs) (15), while a specific loss of GLS could improve antitumor T cell activation (13).”
BackgroundGlutamine gluttony of efferocytes
Jaccard, A., Li, X., & Ho, P. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00462-z · Cited by 5
Yu, Q., Yu, M., Xie, P., Guo, L., Zhao, Y., Xu, W., Li, X., Wu, M., Zhang, Z., Chen, Z., et al. (2025) · Science Advances · doi:10.1126/sciadv.adw6926 · Cited by 4
“Studies have linked YAP1 signaling and glutamine (Gln) metabolism ( 31 – 33 ), both of which are associated with MDSC infiltration ( 25 , 34 – 36 ).”
Self-citationLi, Z., Deng, J., Wang, H., Liu, T., Zhou, Y., Ouyang, P., Liang, X., Zhang, X., Qi, S., & Li, Y. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101834 · Cited by 7
“120 Furthermore, inhibiting Gln metabolism in myeloid-derived suppressor cells causes activation-induced cell death and converts myeloid-derived suppressor cells into inflammatory macrophages.”
Targeting Metabolic Vulnerabilities in Glioblastoma: a Framework for Multi-node Combination Therapy
Gokani, V., Kotta, A., Repaka, V., Rauniyar, S., & Noch, E. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01746-x · Cited by 4
Macrophage Metabolic Reprogramming-Related Osteoimmunity in Osteoporosis
Zhou, K., Wang, Z., & Zhang, M. (2026) · Calcified Tissue International · doi:10.1007/s00223-026-01477-y · Cited by 5
Selective Targeting of STAT6: Recent Advances and Future Perspectives
Liu, H., Ma, F., Wang, Z., Li, Z. A., Bian, J., Yuan, Z., & Wu, T. (2026) · Medicinal Research Reviews · doi:10.1002/med.70069 · Cited by 4
Zhou, S., Li, Y., Wu, R., Chen, T., Xu, Y., Le, H., Tang, Y., Wu, Q., & Gong, C. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102451 · Cited by 5
Portillo‐Miño, J. D., Calderón, J. J., Ruíz‐García, E., & Monge, C. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03960-8 · Cited by 4
“It is responsible for the recruitment of MDSC by CSF3 (colony-stimulating factor 3) pathway [112].”
Study of Drug Resistance in Chemotherapy Induced by Extracellular Vesicles on a Microchip
Fang, T., Lu, W. J., Zhang, J., Ge, K., Chen, Z., Wang, M., & Yao, B. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c04330 · Cited by 5
The impact of broad glutamine metabolism inhibition on the tumor microenvironment
Li, T., Chuang, Y.-T., & Wang, T. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.05.003 · Cited by 4
Amino acid metabolism-mediated immune cell fate and function in pigs
He, L., Jin, S., Li, Y., & Yin, Y. (2025) · Animal Nutriomics · doi:10.1017/anr.2025.5 · Cited by 3
Jiang, F., Huang, X., Yan, M., Tan, J., Dong, X., Liu, X., He, J., Ali, A. M. M., Chen, M., Zhang, L., et al. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/5291562 · Cited by 3
“Glutamine provides energy for cellular metabolism through the glutamine catabolic pathway and provides purine, pyrimidine, and nucleotide bio-synthetic precursors for the synthesis of DNA and mRNA [52].”
Shao, Y., Song, K., Yu, R., He, X., Li, C., Deng, Y., Zhang, Y., & Ren, Y. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5676 · Cited by 5
“Inhibitors like JPH203 and dRP‑104 can reduce glutamine uptake in tumor cells while enhancing cd8 + T cell infiltration and function (114,115).”
Fisher, E. L., Hathaway, E. S., Perera, J. M., Jennings, E. Q., Chi, C., Sewell, A. E., Stone, S. H., Muka, J. E., Sinard, R. C., DeCorte, J. A., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf250 · Cited by 4
DNAJ-PKAc induces metabolic rewiring and enhanced glutamine flux in fibrolamellar HCC
Kamdar, Z. P., Neumann, E., Howe, K., Long, D., Arif, W., Shu, D. H., Mohan, A. A., Kartalia, E., Hernandez, J. P., Levin, S., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.10.027 · Cited by 4
Self-citationBidirectional role of neutrophils in lung cancer: Mechanisms and therapeutic implications
Wang, J., Zhang, M., Cui, Z., Qu, J., & Chang, R. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105087 · Cited by 5
Zhang, X.-M., Zhao, F.-Y., Gao, L.-F., Xu, T., Yang, F., & Qian, N. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i12.110351 · Cited by 3
Gong, W., Taner, H. F., Wu, Y., He, Y., Zhou, X., Li, Z., Hu, X., Ursin, C. A., Debnath, K. C., Okuyama, K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-68027-2 · Cited by 4
Yang, L., Zhang, C., Zhang, Z., Yao, S., Shen, J., Zhang, Z., Xiao, Z., Wang, S., & Wu, Z. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07887-8 · Cited by 4
“Myeloid-derived suppressor cells (MDSCs) and M2 macrophages, on the other hand, rely on amino acid metabolism and fatty acid oxidation-driven oxidative phosphorylation for energy production [77].”
Hong, Z., Wu, Y., Liu, W., Li, D., & Xu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1773233 · Cited by 3
Amino Acid-Driven Mitochondrial Metabolic Rewiring Controls Antitumor Immunity
Ham, S., Jo, M.-J., Song, K., & Choi, B.-H. (2026) · Cancers · doi:10.3390/cancers18091474 · Cited by 3
“The prodrug JHU-083 improves tumor selectivity and demonstrates both tumor suppression and immune-modulatory effects, including reduced myeloid-derived suppressor cell accumulation and enhanced CD8 + T-cell responses [143].”
Talib, W. H., Sabri, S. M., Yousif, R. M., Hadi, R. W., Al-Yasari, I. H., Madhunapantula, S. V., Soós, I., Law, D., & Ács, P. (2026) · Nutrients · doi:10.3390/nu18101515 · Cited by 3
“Therefore, melatonin can interfere in the metabolic reprogramming of tumors cells and hence hinder the growth and development of a tumor [42,55].”
Seliger, B., Mantke, R., Naß, N., Dammermann, W., Ocvirk, S., Kah, J., Kalinski, T., & Massa, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104299 · Cited by 3
“Inhibition of glutaminase in CRC-bearing mice enhanced the production of reactive oxygen species [144], reduced MDSC recruitment [265], and inhibited stromal activation and angiogenesis [266], leading to clinical trials combining the CB-893 glutaminase inhibitor with a MAPK inhibitor or with 5’-FU…”
Metabolic pattern changes of macrophages during cancer development and progression
Liu, G., Wang, B., Wang, S., Shi, L., Han, H., & An, T. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08210-1 · Cited by 3
“In contrast, L-DON can inhibit the release of tumor-derived cytokines (such as granulocyte CSF-3), thereby reducing the production of regulatory immune cells, promoting the expansion and activation of pro-inflammatory macrophage populations, and enhancing antigen presentation to CD8 + T cells [260].”
Coutinho, L. L., Palmieri, E. M., Ridnour, L. A., Cheng, R. Y. S., Heinz, W. F., Anderson, S. K., Billiar, T. R., Chang, J. C., Lockett, S., Rangel, M. C., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104245 · Cited by 4
Metabolic pathway analysis of tumors using stable isotopes
Bi, Q., Zhao, J., Nie, J. H., & Huang, F. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.05.002 · Cited by 3
Al-Khalaifah, H. S., Tolba, S. A., Al-Nasser, A. Y., & Gouda, A. (2025) · Animals · doi:10.3390/ani15101386 · Cited by 3
“Gln is the most prevalent free amino acid (AA) in the body, and apart from its significance in AA transamination and as a protein constituent, Gln has a variety of nonnutritive functions and has been asserted to be essen-Animals tial in certain clinical or stress-related situations [19,20].”
Hao, J., Zhou, C., Wang, Z., Ma, Z., Wu, Z., Lv, Y., & Wu, R. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1084275 · Cited by 3
“Previously study demonstrated that targeting glutamine metabolism could enhance antitumor immunity and decrease tumor growth in breast cancer by promoting the differentiation of myeloid-derived suppressor cells (Oh et al., 2020).”
BackgroundAmino acids and their roles in tumor immunotherapy of breast cancer
Xia, H., Zhu, J., Zheng, Z., Xiao, P., Yu, X., Wu, M., Xue, L., Xu, X. Y., Wang, X., Guo, Y., et al. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3647 · Cited by 3
“79 Gln restriction inhibited the M2 polarization of macrophages, reducing their tumor-promoting effects.”
BackgroundTumoral IL-10-activated SHP2 in macrophages promotes mammary carcinoma progression
Gao, J., Chen, Z., Wang, Y., Guo, L., Fan, M., Zhou, L., Wang, L., Huang, Y., Sun, Y., Guo, W., et al. (2024) · Fundamental Research · doi:10.1016/j.fmre.2024.03.026 · Cited by 3
“In contrast, the typically downregulated genes, including Ptgs2, Csf3, Mmps and Args , were associated with immunosuppression, metastasis and angiogenesis [ 22 , 23 ].”
Wu, J. Y., Ren, A. L., & Lim, M. K. (2022) · Chinese Clinical Oncology · doi:10.21037/cco-22-58 · Cited by 2
Role of glutamine metabolism in tuberculosis pathogenesis: a mini review
Parveen, S., & Bishai, W. R. (2024) · Frontiers in Tuberculosis · doi:10.3389/ftubr.2024.1432880 · Cited by 3
“Accordingly, in murine cancer models, blockade of glutamine metabolism has been shown to deplete MDSCs and Tregs populations and to metabolically reprogram M2 macrophages, alleviating immunosuppression and enhancing anti-tumor T-cell immunity (38–40).”
Immunometabolism in cancer: A journey into innate and adaptive cells
Sant’Ana, A. N., Dias, C. K., Silva, S. K. E., & Figueiró, F. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2401353 · Cited by 2
“…reduces the expression of the immunosuppressive enzyme IDO in these cells, while also promoting apoptosis and the conversion of MDSCs into inflammatory macrophages characterized by the production of TNF-α, as well as the expression of the activation markers CD80, CD86, and MHC-II (Figure 1d) [44].”
Engineering glutamine-regulating nanomedicines for efficient tumor therapy
Hou, G., Lu, S., Chen, Y., Lei, H., Yi, B., & Cheng, L. (2025) · Materials Today · doi:10.1016/j.mattod.2025.09.019 · Cited by 2
Zhu, T., Wei, T.-F., Yang, M., Xu, J., Jiang, H., He, W., Zheng, J., & Dai, H. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.070180 · Cited by 4
“…expression of immune checkpoints such as programmed death-ligand 1 (PD-L1), defective antigen presentation process, and the infiltration of immune-suppressing cells, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), into the tumor microenvironment (TME) [1–3].”
Zhuang, J., Chen, Y., Zhang, Y., Hai, Y., Fan, R., Dou, J., Lu, X., Wang, W., Zhang, B., Hou, Z., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.01.077 · Cited by 2
Reprograms pro-inflammatory differentiation in macrophages
Qi, S., Fan, J., Wu, D.-S., Ganguly, S., Shih, I., & Wang, T. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102104 · Cited by 2
Advances in macrophage metabolic reprogramming in hematological malignancies
Li, X. J., Zuo, S., Xu, L., Song, Y., & Li, W. H. (2025) · Chinese Medical Journal BioMed · doi:10.65457/cmjbm-2025-0001 · Cited by 2
Chakraborty, P., Chatterjee, S., Kassir, M. F., Wofford, W. O., Choi, S., Oleinik, N., Saatci, Ö., Darawshi, O., Das, S., Oberholtzer, N. P., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73827-1 · Cited by 2
“MDSCs also undergo activation-induced cell death and transform into in fl ammatory cells when glutamine metabolism is inhibited 10 .”
Lee, I.-G., & Jung, K. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01759-3 · Cited by 4
He, X., Liu, J., & Wang, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1801318 · Cited by 2
Suru, A. A., Islam, M., Tam, A. J., Gross, J. M., & Llosa, N. J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-sitc2021.580 · Cited by 2
“Glutamine is a key metabolite participating in the TCA cycle and is implicated in sarcoma-genesis [2] and its blockade has shown to skew immune cell function and phenotype [3].”
BackgroundSelf-citationLi, W., Zou, Z., An, N., Wang, M., Liu, X., & Mei, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.996222 · Cited by 2
“Previous studies demonstrated that AAM suppresses the immune function of cancer patients, as well as alters the TME (22, 60).”
BackgroundRetractedXiao, T., Sun, M., Chang, Y., Kang, J., Zhao, C., Zhu, R., Chen, H., & Qiang, Y. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105344 · Cited by 3
[Advances of Immunotherapy Resistance and Coping Strategies in Non-small Cell Lung Cancer].
Jing, Y., Zeng, H., Cheng, R., Tian, P., & Li, Y. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.102.03 · Cited by 4
Wang, C., Feng, Q., Lu, H., He, Q., Zhang, P., Tang, J., Liu, Z., Liu, J., & Chen, B. (2024) · Materials Today Nano · doi:10.1016/j.mtnano.2024.100509 · Cited by 3
Peripheral nerves-cancer cross-talk: the next frontier in cancer treatment
Wang, L., Qi, T., Tang, L., Wang, Y., ChenLiu, Z., Wang, D., & Tang, D. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05256-5 · Cited by 2
“The orally active Gln antagonist prodrug, JHU083, targets Gln metabolism and enhances antitumor effects by inducing apoptosis in MDSCs, enhancing immunogenic tumor cell death and antigen presentation by TAMs, and promoting cytotoxic responses in CD8 + T cells [86].”
Knowing the myeloid-derived suppressor cells: Another enemy of sarcomas patients
García-Domínguez, D. J., Sánchez‐Margalet, V., de la Cruz‐Merino, L., & Hontecillas‐Prieto, L. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2022.11.003 · Cited by 2
Dias, A. S., Almeida, C. R., Helguero, L. A., & Duarte, I. F. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00654 · Cited by 2
Spotlighting cellular therapies to advance the treatment of medulloblastoma
Ligon, J. A., & Sayour, E. J. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad005 · Cited by 2
Chortis, V., Borges, K. S., Yao, C.-H., Ribeiro, C. H. T., Nagano, L. F. P., Berber, M., Prete, A., Najdekr, L., Klontzas, M. E., Jankevics, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.28.674326 · Cited by 2
Myeloid cells: key players in tumor microenvironments
Hua, Q., Li, Z., Weng, Y., Wu, Y., & Zheng, L. (2025) · Frontiers of Medicine · doi:10.1007/s11684-025-1124-8 · Cited by 1
Hashinokuchi, A., Haratake, N., Ono, Y., Tomonaga, T., Bassi, G., Matsudo, K., Kinoshita, F., Matsubara, T., Kohno, M., Takenaka, T., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02851-w · Cited by 1
Wang, Y., Li, P., Feng, T., Chen, Y., Liu, W., Ge, Q., & Zhang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1630053 · Cited by 1
“In addition, as a non-essential amino acid, glutamine supplies materials for the TCA cycle and amidotransferase pathways in RCC, and some inhibitors that are speci fi c to glutamine metabolism were put into effect, which led to modest growth suppression in RCC cells (58 – 60).”
Yu, L., & Xia, L. (2025) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2025.08.006 · Cited by 1
Wang, S., Zheng, M., & Yang, J. (2025) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-025-03685-3 · Cited by 1
“Despite its potential significance, the specific contribution of Gln metabolism to immune modulation in AS remains largely unexplored [11].”
The pivotal role of metabolism in shaping tumor-associated macrophages phenotype and function.
Jun, M., Li, T.-T., Shi, Y., Yin, H., Wu, W., Dong, X., He, X., & Lai, X. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116547 · Cited by 2
Ruan, Z., & Sun, X. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2025.58 · Cited by 2
Targeting glutamine metabolism to modulate macrophage functions in the tumor microenvironment
Wu, S., Peng, Y., Wang, Q. J., Li, Z., Ge, K., & Ye, L. (2026) · Discover Oncology · doi:10.1007/s12672-026-04999-x · Cited by 2
“These compounds reverse immunosuppressive conditions in the TME and restore immune cell-mediated tumor killing [88, 90–92].”
InfluentialCancer metabolism: from the Warburg effect to precision therapy
王璨璇, Wang, J., Miao, L., Wei, L., Liu, X., Lu, Y., Xiang, L., & Zhang, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1793553 · Cited by 1
Endogenous metabolite signaling orchestrates tumor immune evasion
Liu, X., Jiang, C., & Li, Y. (2026) · Cell Insight · doi:10.1016/j.cellin.2026.100330 · Cited by 1
Metabolic–epigenetic crosstalk in innate immune cell plasticity within the tumor microenvironment
Noh, J., Lee, J., You, C., & Kang, K. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01802-3 · Cited by 1
“Glutamine antagonists such as JHU083 target tumor cells and MDSCs to restrain expansion, suppress IDO1 and kynurenine signaling, and enhance the immunotherapy response 44 .”
Xu, H. N., Kollmar, J., Podsednik, A., Wannousse, M., Shestov, A., O’Connor, R. S., Baur, J. A., Tchou, J. C., Zhou, R., & Li, L. Z. (2026) · Metabolites · doi:10.3390/metabo16090613 · Cited by 1
“For example, inhibition of glutamine metabolism has been shown to enhance tumor-specific immunity by modulating suppressive myeloid cells in a mouse TNBC model [57].”
Wu, Y., Zhu, X., & Zhu, L. (2022) · Current Protein and Peptide Science · doi:10.2174/1389203723666220620161742 · Cited by 1
Bollino, D. R., Hameed, K. M., Bhat, A. G., Zarrabi, A., Casildo, A., Ma, X., Tighe, K. M., Carter‐Cooper, B., Strovel, E. T., Lapidus, R. G., et al. (2024) · Cancer & Metabolism · doi:10.1186/s40170-024-00346-2 · Cited by 1
“In ALL, numerous studies have reported that ASNS expression is elevated in asparaginase-resistant leukemia cells compared to aspar-aginase-sensitive cells [23, 24], and ASNS expression levels have been correlated with asparaginase sensitivity in PDAC cell lines [29].”
BackgroundComputational modeling of metabolism in oncology
Fong, L. E., Jin, M., Kharbanda, S., Creixell, M., Wu, X., Zhang, D., Dubrot, J., Yates, K. B., Manguso, R. T., Kaufmann-Malaga, B., et al. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-15447-8.00005-2 · Cited by 1
Self-citationGlutamine: A bad guy for antitumor immunity?
Shi, L. Z. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb7093 · Cited by 1
Autophagy disruption primes CAR-T cell metabolism for sustained rejection of ovarian tumorsPreprint
Carleton, G. A., Levesque, S., Zacharias, L. G., Patrício, J. S., Sutcliffe, T., Watson, P. H., DeBerardinis, R. J., Doyon, Y., & Lum, J. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.09.681473 · Cited by 1
Robust metabolic transcriptional components in 34,494 patient-derived samples and cell linesPreprint
Leeuwenburgh, V. C., Urzúa-Traslaviña, C. G., Bhattacharya, A., Walvoort, M. T. C., Jalving, M., de Jong, S., & Fehrmann, R. S. N. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.01.321950
“…glutamine metabolism has been shown to inhibit tumor growth and increase the sensitivity of triple-negative breast cancers to immune checkpoint blockade (Oh et al., 2020), and reducing oxidative stress has been shown to prevent the generation of tumor-associated macrophages (Zhang et al., 2013).”
BackgroundRobust Metabolic Transcriptional Components in 34,494 Patient-Derived Samples and Cell LinesPreprint
Leeuwenburgh, V. C., Urzúa-Traslaviña, C. G., Bhattacharya, A., Walvoort, M. T. C., Jalving, M., de Jong, S., & Fehrmann, R. S. N. (2021) · Research Square · doi:10.21203/rs.3.rs-659596/v1
Targeting the Immuno-Oncology Metabolism in Cancer
Tripathi, S. C., Fahrmann, J. F., & Amle, D. B. (2022) · Springer eBooks · doi:10.1007/978-981-16-6226-3_5
Bajia, D., Ambe, G. N. N. N., & Derwich, K. (2022) · Journal of Biomedical Research & Environmental Sciences · doi:10.37871/jbres1622
Varghese, S., Pramanik, S., Williams, L. J., Hodges, H. R., Hudgens, C. W., Fischer, G. M., Luo, C. K., Knighton, B. G., Tan, L., Lorenzi, P. L., et al. (2023) · doi:10.1158/1535-7163.c.6542659
Suru, A. A., Maalouf, A., Zhao, L., Tam, A. J., Zhang, L., Doucet, M., Islam, M., Jamil, Z., Meyer, C. F., Morris, C. D., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-sitc2023.0854
Self-citationLillo, S. (2023) · theses.fr (ABES) · doi:10.70675/49be81c2z656fz400dzbc64z391cf8330a65
Muradova, Z. (2021) · theses.fr (ABES) · doi:10.70675/5fb3db8ez4393z43f9zbe6czc5a5df1da7cd
Metadata
- Authors
- Oh, M.-H., Sun, I.-H., Zhao, L., Leone, R. D., Sun, I.-M., Xu, W., Collins, S. L., Tam, A. J., Blosser, R. L., Patel, C. H., Englert, J. M., Arwood, M. L., Wen, J., Chan-Li, Y., Tenora, L., Majer, P., Rais, R., Slusher, B. S., Horton, M. R., & Powell, J. D.
- Affiliations
- Johns Hopkins University (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- UPMC Enterprises (United States) (US)
- Czech Academy of Sciences, Institute of Organic Chemistry and Biochemistry (CZ)
- Corresponding author
- Powell, Jonathan D.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2020-06-15
- Volume
- 130
- Issue
- 7
- Pages
- 3865-3884
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3020598614
- Cited by
- 456
- References
- 66
- Citations by year
- 2026: 72 · 2025: 86 · 2024: 77 · 2023: 89 · 2022: 65 · 2021: 49 · 2020: 18
- FWCI
- 19.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH Office of the Director (R01CA229451, S10 OD016374, R01HL141490, R01AI077610, R01CA226765)
- Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University (N/A)
- Under Armour Women’s Health & Breast Cancer Innovation Grants (N/A)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- glutamine metabolism, myeloid-derived suppressor cells, tumor microenvironment, tumor-associated macrophages, immunogenic cell death, granulocyte colony-stimulating factor, IDO, kynurenine, immunometabolism, metastasis, antitumor immunity, small molecule inhibitors
- MeSH terms
- Myeloid-Derived Suppressor Cells, Animals, Female, Glutamine, Immunity, Cellular, Immunotherapy, Macrophages, Male, Mice, Inbred BALB C, Neoplasms, Experimental, Mice, Knockout, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.